Issues in the management of Alzheimer's disease

Martin Farlow, Fraser Inglis

Research output: Contribution to journalReview article


The cholinesterase inhibitors are widely accepted as being the gold standard treatment for mild-to-moderate AD. Recent data support the early initiation and continued use of these agents over the long term. However, the current average duration of treatment is less than one year, possibly due to disappointing efficacy of the initial treatment. In such cases, pharmacological differences between available cholinesterase inhibitors provide a good rationale to switch to another drug in the same class. For example, evidence from two prospective studies has shown that about 50% of patients failing to benefit from donepezil treatment experienced significant improvements after being switched to rivastjgmine. Pharmacological differences between available cholinesterase inhibitors may determine differences in their clinical profiles, and switching strategies may be employed to provide optimal, long-term benefits.

Original languageEnglish (US)
Pages (from-to)107-108
Number of pages2
JournalPrimary Care Psychiatry
Issue number3
StatePublished - Sep 1 2002


  • Alzheimer's disease
  • Cholinesterase inhibitors
  • Clinical practice
  • Donepezil
  • Rivastigmine
  • Switching strategies

ASJC Scopus subject areas

  • Psychiatry and Mental health

Fingerprint Dive into the research topics of 'Issues in the management of Alzheimer's disease'. Together they form a unique fingerprint.

  • Cite this